Silverfin false false 31/12/2023 01/01/2023 31/12/2023 A Keeling 05/11/2021 D Keeling 29/11/2013 25 September 2024 no description of principal activity 08797010 2023-12-31 08797010 bus:Director1 2023-12-31 08797010 bus:Director2 2023-12-31 08797010 2022-12-31 08797010 core:CurrentFinancialInstruments 2023-12-31 08797010 core:CurrentFinancialInstruments 2022-12-31 08797010 core:ShareCapital 2023-12-31 08797010 core:ShareCapital 2022-12-31 08797010 core:RetainedEarningsAccumulatedLosses 2023-12-31 08797010 core:RetainedEarningsAccumulatedLosses 2022-12-31 08797010 core:CostValuation 2022-12-31 08797010 core:CostValuation 2023-12-31 08797010 2023-01-01 2023-12-31 08797010 bus:FilletedAccounts 2023-01-01 2023-12-31 08797010 bus:SmallEntities 2023-01-01 2023-12-31 08797010 bus:AuditExemptWithAccountantsReport 2023-01-01 2023-12-31 08797010 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 08797010 bus:Director1 2023-01-01 2023-12-31 08797010 bus:Director2 2023-01-01 2023-12-31 08797010 2021-12-01 2022-12-31 iso4217:GBP xbrli:pure

Company No: 08797010 (England and Wales)

INJURY ASSESS MEDICALS LIMITED

Unaudited Financial Statements
For the financial year ended 31 December 2023
Pages for filing with the registrar

INJURY ASSESS MEDICALS LIMITED

Unaudited Financial Statements

For the financial year ended 31 December 2023

Contents

INJURY ASSESS MEDICALS LIMITED

BALANCE SHEET

As at 31 December 2023
INJURY ASSESS MEDICALS LIMITED

BALANCE SHEET (continued)

As at 31 December 2023
Note 31.12.2023 31.12.2022
£ £
Fixed assets
Investments 3 2 2
2 2
Current assets
Debtors 4 25,880 19,050
Cash at bank and in hand 43 110
25,923 19,160
Creditors: amounts falling due within one year 5 ( 15,976) ( 11,821)
Net current assets 9,947 7,339
Total assets less current liabilities 9,949 7,341
Net assets 9,949 7,341
Capital and reserves
Called-up share capital 10 10
Profit and loss account 9,939 7,331
Total shareholder's funds 9,949 7,341

For the financial year ending 31 December 2023 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Injury Assess Medicals Limited (registered number: 08797010) were approved and authorised for issue by the Board of Directors on 25 September 2024. They were signed on its behalf by:

A Keeling
Director
INJURY ASSESS MEDICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023
INJURY ASSESS MEDICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Injury Assess Medicals Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 5 Woodcote View, Wilmslow, SK9 2DT, England, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Turnover

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following criteria must also be met before revenue is recognised:

Turnover is derived from intermediation between medical professionals and legal teams on behalf of solicitors.

Revenue is measured at the fair value of invoices raised in respect of physiotherapy and medical appointments, net of discounts and excluding value added tax, and is recognised at the date the appointment is booked.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Investments
Investments in subsidiaries are measured at cost less accumulated impairment.

2. Employees

Year ended
31.12.2023
Period from
01.12.2021 to
31.12.2022
Number Number
Monthly average number of persons employed by the Company during the period 0 0

The directors did not receive any remuneration in the year (2022: £nil).

3. Fixed asset investments

Investments in subsidiaries

31.12.2023
£
Cost
At 01 January 2023 2
At 31 December 2023 2
Carrying value at 31 December 2023 2
Carrying value at 31 December 2022 2

4. Debtors

31.12.2023 31.12.2022
£ £
Trade debtors 8,850 5,473
Amounts owed by directors 13,524 9,550
Other debtors 3,506 4,027
25,880 19,050

5. Creditors: amounts falling due within one year

31.12.2023 31.12.2022
£ £
Trade creditors 5,657 3,018
Amounts owed to Group undertakings 3,212 2,057
Corporation tax 4,922 4,593
Other taxation and social security 746 713
Other creditors 1,439 1,440
15,976 11,821

6. Related party transactions

Transactions with the entity's directors

During the year advances of £3,700 were paid to Mrs A Keeling. The maximum advanced during the year was £13,250 (2022: £9,550). No repayments were made during the year (2022: £nil). At the balance sheet date the outstanding balance was £13,524 (2022: £9,550). The loan attracts interest at 2.25% and is repayable on demand.

Other related party transactions

During the prior year, the company paid expenses on behalf of a company with directors in common. The amount advanced was £nil (2022: £848). At the balance sheet date, the outstanding balance was £848 (2022: £848).